Subscribe our newsletter
Please Subscribe our news letter and get update.
Close
Key driving factors of Point of care market include favorable regulations for point of care testing, Global rise in infectious diseases, such as HIV, Tuberculosis, Influenza, etc. and Advent of next generation point of care diagnostics technology. Challenges in the PoC domain include limited adoption of the devices due to lack of accuracy and high pricing due to reimbursement cuts. The global point-of-care diagnostics market is estimated to be valued at ~ $45 Billion in 2023, and is expected to grow at a CAGR of 8-9%. Glucose Monitoring products have held a significant share in the market since 2021, with Lateral Flow Assay dominating the market share by Platform.
Key players in point-of-care are Siemens Healthineers, Danaher Corporation, Abbott Laboratories, GE Healthcare,F. Hoffmann-La Roche and BD. Recent activities feature the FDA clearance of Abbott’s two new over-the-counter continuous glucose monitors, Lingo and Libre Rio (June, 2024). and acquisition of LumiraDx’s point-of-care technology by Roche for USD 295 Million, which will significantly expand the firm’s PoC portfolio (Jan, 2024)
POINT-OF-CARE TESTING MARKET DYNAMICS
Drivers: Advent of new-generation point of care diagnostics globally
The advent of new-generation point-of-care (POC) diagnostics is a key driver for market growth globally. These advanced devices, enhanced by technologies like biosensors, microfluidics, and artificial intelligence (AI), offer accurate and rapid testing at the patient’s side.
According to World Health Organization (WHO) statistics for 2021, ~38.4 million people worldwide were still living with HIV, and 0.65 million people died from HIV-related causes. Smart POCT devices, empowered by IoMT and AI, are revolutionizing AIDS patient care by enabling remote monitoring, reducing discrimination, and improving treatment accessibility. These technologies enhance result interpretation, extend healthcare reach to underserved areas, and foster better connectivity between devices and medical professionals, driving innovation in point-of-care testing.
Opportunities: High growth potential of emerging markets
Due to rapid urbanization, the emerging economies are impacting the rise of demand of better healthcare and treatments, creating an improved healthcare infrastructure and hence boosting healthcare expenditure and growing healthcare insurance systems. The rise in prevalence of infectious diseases in these world sectors have also grown the need for better point-of-care testing exponentially.
In the IDF Diabetes Atlas 2021 study, a rise of 69.89% cases of diabetes was observed in South Africa, India, Brazil, China, Malaysia and Thailand, reflecting a high potential for adoption of point-of-care testing kits for blood glucose.
Challenges: Adoption of the devices maybe limited due to Lack of Accuracy
Accuracy challenges pose a significant barrier to the widespread adoption of point-of-care testing (POCT) devices. Despite their convenience, some POCT devices may produce less reliable results compared to centralized laboratory testing, leading to potential misdiagnosis or inappropriate treatment decisions. This accuracy gap can stem from factors such as:
Healthcare providers and patients may hesitate to fully rely on POCT results, potentially slowing market growth and integration into clinical workflows. Overcoming these accuracy concerns through technological advancements and improved quality control measures is crucial for the future success of POCT.
GLOBAL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE
Glucose monitoring devices dominated the PoC market share in 2023
Point-of-care testing encompasses various product types, including glucose monitoring devices (strips, meters, lancing devices), COVID-19 testing kits, cardio-metabolic monitoring tools (cardiac markers, electrolyte testers, HBA1C testers), and infectious disease testing products. Each category serves specific diagnostic needs, allowing for rapid on-site testing across different medical conditions. Among these, Glucose monitoring devices dominate the market share, primarily due to the high prevalence of diabetes globally and the need for frequent blood glucose measurements by patients for effective disease management.
GLOBAL POINT-OF-CARE TESTING MARKET, BY PLATFORM
Lateral flow assay held the largest share in 2023
Point-of-care testing employs diverse platforms including immunoassays, lateral flow assays, microfluidics, dipsticks, and molecular diagnostics. Each offers unique advantages: immunoassays detect specific proteins, microfluidics enables precise small-volume analysis, dipsticks provide quick chemical results, and molecular diagnostics offer highly specific genetic testing. However, lateral flow assays dominate the market due to their simplicity, cost-effectiveness, and versatility across multiple diagnostic applications.
GLOBAL POINT-OF-CARE TESTING MARKET, BY END USER
Significant growth in self-testing and home care was observed in 2023-2030
Point-of-care testing serves various end-users: clinical labs for specialized diagnostics, ambulatory facilities for outpatient care, hospitals and critical care centers for immediate bedside testing, and homecare settings for patient self-monitoring. While traditional healthcare facilities remain significant users, recent trends show notable growth in homecare settings and self-testing. This shift reflects increasing patient autonomy, the rise of telemedicine, and the development of user-friendly diagnostic devices suitable for non-clinical environments.
GLOBAL POINT-OF-CARE TESTING MARKET, BY REGION
North America held the largest market share in PoC testing in the forecast period
The point-of-care (PoC) diagnostics market research encompassed a comprehensive analysis of five key regions: North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. Each region was evaluated based on factors such as healthcare infrastructure, regulatory landscape, technological adoption, and market dynamics. The research revealed that North America held the largest share in the PoC industry during the forecast period, primarily due to its advanced healthcare systems, high adoption rates of new technologies, favorable reimbursement policies, and the presence of major market players driving innovation in this sector.
As per the Historical and the base year of the report (2022 and 2023, respectively), Key players in Point-of-care were Abbott Laboratories (US), GE Healthcare (US), Siemens Healthineers (Germany), Danaher Corporation (US), F. Hoffmann-La Roche (Switzerland) and BD (US).
Introduction
Market Definition
Point-of-care testing (POCT) is revolutionizing healthcare delivery by bringing diagnostic capabilities directly to patient care sites. This market is experiencing rapid growth, driven by the rising prevalence of chronic conditions like diabetes, heart disease, and infectious illnesses. In the U.S. alone, CDC data from 2021 indicates that 38.4 million people have diabetes, highlighting the vast potential for POCT applications.
The POCT market’s expansion is fueled by key benefits including:
As healthcare systems worldwide seek to improve patient outcomes while managing costs, POCT offers a compelling solution. This technology enables quick decision-making, reduces hospital visits, and allows for more personalized treatment plans. With the global trend towards patient-centered care and the increasing need for efficient diagnostic tools, the POCT market is poised for continued growth and innovation across various healthcare settings.
FIGURE: POINT-OF-CARE TESTING MARKET SEGMENT
FIGURE: YEARS FRAMEWORK CONSIDERED IN THE STUDY
Key Stakeholders
Key objectives of the Study
Research Methodology
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as product launches and approvals, expansions, and collaborations of the leading players, the competitive landscape of the point of care testing market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches will be used to estimate the market size. To estimate the market size of segments and sub segments the market breakdown and data triangulation will be used.
FIGURE: RESEARCH DESIGN
Research Approach
Collecting Secondary Data
The secondary research data collection process involves the usage of secondary sources, directories, databases, annual reports, investor presentations, and SEC filings of companies. Secondary research will be used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the point of care testing market. A database of the key industry leaders will also be prepared using secondary research.
Collecting Primary Data
The primary research data will be conducted after acquiring knowledge about the point of care testing market scenario through secondary research. A significant number of primary interviews will be conducted with stakeholders from both the demand side and supply side (including various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers) across major countries of North America, Europe, Asia Pacific, and Rest of the World. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM SUPPLY SIDE
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM DEMAND SIDE
FIGURE: PROPOSED PRIMARY PARTICIPANTS FROM DEMAND AND SUPPLY SIDE
Market Size Estimation
All major manufacturers offering various point of care testing systems will be identified at the global/regional level. Revenue mapping will be done for the major players, which will further be extrapolated to arrive at the global market value of each type of segment. The market value of point of care testing market will also split into various segments and sub segments at the region level based on:
Product and services mapping of various players for each type of point of care testing market at the regional-level
FIGURE: REVENUE MAPPING BY COMPANY (ILLUSTRATION)
FIGURE: REVENUE SHARE ANALYSIS OF KEY PLAYERS (SUPPLY SIDE)
FIGURE: MARKET SIZE ESTIMATION TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE: ANALYSIS OF DROCS FOR GROWTH FORECAST
FIGURE: GROWTH FORECAST ANALYSIS UTILIZING MULTIPLE PARAMETERS
Research Design
After arriving at the overall market size-using the market size estimation processes-the market will be split into several segments and sub segment. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub segment, the data triangulation, and market breakdown procedures will be employed, wherever applicable. The data will be triangulated by studying various factors and trends from both the demand and supply sides in the point of care testing market industry.
Sample Company Profile – Abbott Laboratories
Business Overview
Abbott Laboratories is an American multinational medical devices and health care. It develops and sells medical devices, diagnostics, branded generic medicines and nutritional products.
FIGURE: Financial Snapshot: Abbott Laboratories (2023)
Note: R&D expenditure is provided as % of the total revenue.
Product Portfolio
Key Product(s)/Technology(s) | Description |
BinaxNOW™ (COVID-19 testing kit) | The BinaxNOW COVID-19 Ag Card is a lateral flow immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal (nares) swab specimens. |
FreeStyle Libre | The FreeStyle Libre is a continuous glucose monitoring system, indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus. |
ID NOW™ Influenza A & B 2 | The ID NOW™ Influenza A & B 2 assay delivers molecular flu results in 13 minutes or less on Abbott’s unique ID NOW™ platform; making it significantly faster than other molecular methods and more accurate than conventional rapid tests. |
i-STAT 1 | The i-STAT 1 is a portable blood analysis system that delivers lab-quality diagnostic results in minutes. This blood analyzer operates with the advanced technology of i-STAT test cartridges. Together, they create the i-STAT System — a point-of-care-testing platform that provides healthcare professionals with diagnostic information |
Cholestech LDX™ Analyzer | The Cholestech LDX™ Analyzer provides accurate, actionable, and readily accessible results that have set the standard in point-of-care lipid profile, cholesterol, and glucose testing. |
Recent Development(s)
Type of Development | Month | Year | Description | Impact |
FDA Clearance | April | 2024 | The company received FDA clearance for Point-of-Care TBI Test, expanding brain injury diagnostic portfolio. The test is developed in collaboration with the U.S. Department of Defense over the past decade, utilizes two key biomarkers: glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1). | The firm has further expanded and strengthened its PoC product portfolio. |
Marketing and Promotion Agreement | May | 2021 | Generic Pharmasec has entered into an agreement with Abbott Point of Care (APOC), the medical and diagnostics devices division of Abbott, for the distribution, marketing and promotion of the entire range of products by APOC in the entire country of India. The agreement covers the entire length and breadth of the country. | This will increase the companies penetration into the Indian market by at least 1,000 additional hospital set-ups in the next 24 months by creating long-term strategies for marketing and promotion. |
FDA Clearance | June | 2024 | The firm secured FDA clearance for two new Over-the-Counter Continuous Glucose Monitors: Lingo and Libre Rio. They target distinct markets, expanding access to FreeStyle Libre technology beyond traditional diabetes care | This FDA clearance positions the frim to tap into both the growing wellness market and the underserved segment of Type 2 diabetes patients. The move could potentially reshape the landscape of glucose monitoring. |
1. Introduction
1.1 Key Objectives
1.2 Definitions
1.2.1 In Scope
1.2.2 Out of Scope
1.3 Scope of the Report
1.4 Scope Related Limitations
1.5 Key Stakeholders
2. Research Methodology
2.1 Research Approach
2.2 Research Methodology / Design
2.3 Market Sizing Approach
2.3.1 Secondary Research
2.3.2 Primary Research
3. Executive Summary & Premium Content
3.1 Global Market Outlook
3.2 Key Market Findings
4. Market Overview
4.1 Market Dynamics
4.1.1 Drivers/Opportunities
4.1.2 Restraints/Challenges
4.2 End User Perception
4.3 Need Gap
4.4 Supply Chain / Value Chain Analysis
4.5 Industry Trends
4.6 Porter’s Five Forces Analysis
5. Patent Analysis
5.1 Patents Related to Point of Care Testing Technologies/Devices
5.2 Patent Landscape and Intellectual Property Trends
6. Point of Care Testing Market, by Product (2023-2030, USD Million)
6.1 Glucose Monitoring Products
6.1.1 Strips
6.1.2 Meters
6.1.3 Lancing Devices
6.1.4 Others
6.2 COVID-19 Testing Products
6.3 Cardio-metabolic Monitoring Products
6.3.1 Cardiac Markers
6.3.2 Electrolyte Tester
6.3.3 HBA1C Tester
6.3.4 Others
6.4 Infectious Disease Testing Products
6.5 Others
7. Point of Care Testing Market, by Platform (2023-2030, USD Million)
7.1 Immunoassays
7.2 Lateral Flow Assay
7.3 Microfluidics
7.4 Dipsticks
7.5 Molecular Diagnostics
7.5.1 RT-PCR
7.5.2 INAAT
7.5.3 Others
8. Point of Care Testing Market, by Sample (2023-2030, USD Million)
8.1 Blood Samples
8.2 Urine Samples
8.3 Nasal and Oropharyngeal Swabs
8.4 Others
9. Point of Care Testing Market, by End Users (2023-2030, USD Million)
9.1 Clinical Labs
9.2 Ambulatory Facilities
9.3 Hospitals and Critical Care Centres
9.4 Others
10. Point of Care Testing Market, by Region (2023-2030, USD Million)
10.1 North America
10.1.1 USA
10.1.2 Canada
10.2 Europe
10.2.1 UK
10.2.2 France
10.2.3 Germany
10.2.4 Italy
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 China
10.3.2 India
10.3.3 Japan
10.3.4 Australia and New Zealand
10.3.5 Rest of Asia-Pacific
10.4 Middle East and Africa
10.5 Latin America
11. Competitive Analysis
11.1 Key Players Footprint Analysis
11.2 Market Share Analysis
11.3 Key Brand Analysis
11.4 Regional Snapshot of Key Players
11.5 R&D Expenditure of Key Players
12. Company Profiles2
12.1 Abbott Laboratories
12.1.1 Business Overview
12.1.2 Product Portfolio
12.1.3 Financial Snapshot3
12.1.4 Recent Developments
12.1.5 SWOT Analysis
12.2 Hoffmann-La Roche Ltd.
12.3 Siemens Healthineers
12.4 Danaher Corporation
12.5 Becton, Dickinson and Company
12.6 Thermo Fisher Scientific Inc.
12.7 Biomrieux
12.8 Quidelortho Corporation
12.9 Trinity Biotech PLC
12.10 Nova Biomedical
12.11 Others Key Players
13. Conclusion
14. Appendix
14.1 Industry Speak
14.2 Questionnaire
14.3 Available Custom Work
14.4 Adjacent Studies
14.5 Authors
15. References
Key Notes:
Note 1 – Contents in the ToC / market segments are tentative and might change as the research proceeds.
Note 2 – List of companies is not exhaustive and might change during the course of study.
Note 3 – Details on key financials might not be captured in case of unlisted companies.
Note 4 – SWOT analysis will be provided for top 3-5 companies.
Note 5 – In scope and out of scope will be provided in detail during the course of the study.